CONNECT WITH US
HealthTech

HealthTech

New brain tumor test could transform diagnosis and treatment

Medical Xpress logo

Published on

Add as a preferred source on Google
New brain tumor test could transform diagnosis and treatment

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Scientists and doctors at Newcastle are among the first in the U.K. to use a pioneering brain tumor test with the potential to speed up diagnosis for patients—from weeks to hours.

The new ultra-rapid test could improve diagnosis and treatment for thousands of patients with brain tumors, which can be aggressive and challenging to treat.

Brain tumors are the biggest cancer killer of children and adults under 40, according to The Brain Tumour Charity.

There are currently more than 100 identified types of brain tumor, and clinicians need to identify which kind a patient has to determine the most effective way to treat them.

Identifying the exact tumor type as quickly as possible is vital to ensuring patients receive timely, often lifesaving cancer care while reducing the stressful wait for them and their families.

Newcastle University, working in partnership with Newcastle Hospitals, is one of five specialist centers across the country forming a new network of excellence. Scientists and doctors will be "early adopters," gathering more evidence about the test's effectiveness for adults and children with brain tumors.

Dr. Jonathan Coxhead, head of the Genomics Core Facility at Newcastle University, said, "This is a fantastic opportunity to work with the Newcastle Hospitals team to help drive the adoption of this test in the NHS.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.